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Background: Lyme borreliosis is the most common vector-borne disease in Europe and North America. The objective
of this study is to estimate the incidence of tick bites and Lyme borreliosis, representative of our entire country, including
erythema migrans, disseminated Lyme borreliosis and persisting symptoms attributed to Lyme borreliosis.
Methods: A questionnaire on clinical diagnoses of Lyme borreliosis was sent to all GPs, company physicians, and medical
specialists. To adjust for possible misclassification and telescoping bias, we sent additional questionnaires to categorize
reported cases according to likelihood of the diagnosis and to exclude cases diagnosed outside the target period.
Results: Adjusted annual incidence rate for disseminated Lyme borreliosis was 7.7 GP reports per 100,000 inhabitants, and
for persisting symptoms attributed to Lyme borreliosis was 5.5 GP reports per 100,000 inhabitants, i.e. approximately 1,300
and 900 cases respectively. GP consultations for tick bites and erythema migrans diagnoses were 495 and 132 per 100,000
inhabitants, respectively, i.e. 82,000 and 22,000 cases in 2010.
Conclusions: This is the first reported nationwide physician survey on the incidence of tick bites and the whole range of
manifestations of Lyme borreliosis, including persisting symptoms attributed to Lyme borreliosis. This is crucial for
complete assessment of the public health impact of Lyme borreliosis.
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Lyme borreliosis is an infectious disease caused by Borrelia
burgdorferi sensu lato species, and transmitted through tick
bites. The disease most commonly manifests as erythema
migrans, a slowly expanding skin lesion indicating early
localized infection. If the infection spreads to other tissues
and organs, it can cause disseminated Lyme borreliosis such
as Lyme neuroborreliosis, Lyme arthritis, borrelial lympho-
cytoma, acrodermatitis chronica atrophicans, Lyme carditis
or ocular manifestations. Occasionally, symptoms persist
after treatment [1]. Marked increases in the incidence of
Lyme borreliosis have been reported over the past decades
in several European countries [2-4] and in North America
[5,6]. Assessment of the disease burden of Lyme borreliosis
requires incidence estimates of all disease outcomes of Lyme
borreliosis, ranging from the most common relatively mild
early manifestation erythema migrans to the more severe
disseminated Lyme borreliosis manifestations, and even* Correspondence: Agnetha.Hofhuis@rivm.nl
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unless otherwise stated.persisting symptoms attributed to Lyme borreliosis. How-
ever, few incidence estimates from European countries
cover all disease expressions of Lyme borreliosis within
one surveillance system or survey, representative for a
whole country [1-4,7].
Underreporting and misclassification are common to all
surveillance systems, and if only high-risk regions are
studied, data collections are not representative for whole
countries. Particularly with Lyme borreliosis, surveillance
is complicated due to the non-specific nature of some dis-
ease expressions and the pitfalls of laboratory diagnostics
[1-4]. The majority of European countries, including the
Netherlands, have not made Lyme borreliosis manda-
torily notifiable [2-4]. Most countrywide incidence esti-
mates of Lyme borreliosis in Europe are based on passive
reporting laboratory surveillance, using the available de-
tails of patients with positive laboratory tests. Unfortu-
nately, erythema migrans is heavily underreported with
laboratory surveillance for Lyme borreliosis, because ery-
thema migrans cases are seronegative at presentation, and
serologic testing is not routinely requested for erythema. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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overreported with laboratory surveillance, due to seroposi-
tivity linked to past exposure [1-4]. Other frequently ap-
plied approaches to collecting data on the occurrence of
Lyme borreliosis and the relative frequency of its disease
manifestations include monitoring of hospital in- and out-
patient diagnoses, and physician surveys [8-14]. However
none of the published incidence estimations represent the
whole country, with exception of two published surveys in
France [8,9], based on their GP sentinel surveillance net-
work (a representative selection of all GP’s) and discharge
reports of all hospitals.
In the Netherlands, periodic nationwide cross-sectional
retrospective studies among general practitioners (GPs)
have revealed a continuing and strong increase in GP con-
sultations for tick bites and erythema migrans between
1994 and 2009. The incidence of tick bite consultations in-
creased linearly from 191 per 100,000 in 1994 to 564 per
100,000 inhabitants in 2009, and concurrently the incidence
of erythema migrans diagnoses increased from 39 to 134
per 100,000 inhabitants [15-18]. Apart from these nation-
wide accurate incidence rates for tick bites and erythema
migrans over time, the incidence of other manifestations of
Lyme borreliosis remained unknown. Furthermore, reports
on the occurrence of Lyme borreliosis have not yet touched
on the relative occurrence of persisting symptoms attrib-
uted to Lyme borreliosis [1-4]. Especially such long-term
persisting conditions, with sometimes disabling symptoms,
and these can have a great impact on the disease burden
and cost-of-illness [1,19].
The objective of the current study is to estimate the
incidence of tick bites and the whole range of disease
expressions of Lyme borreliosis, including erythema
migrans, disseminated Lyme borreliosis and persisting
symptoms attributed to Lyme borreliosis. To achieve
this, we repeated our earlier nationwide GP surveys,
this time including all manifestations of Lyme borrelio-
sis, surveying all GPs, company physicians, and medical
specialists who might be involved in the diagnosis of
Lyme borreliosis.
Methods
To rapidly assess a nationwide representative incidence rate
for Lyme borreliosis, we performed a two-step approach.
Firstly, a broad inquiry was required to also detect the less
common disease manifestations. We sent a two-page retro-
spective questionnaire to all physicians possibly involved in
the diagnosis and treatment of Lyme borreliosis in our
country: 9178 GPs, 1321 company physicians (i.e. physi-
cians to employee groups, vocational physicians from the
private sector), and 5374 medical specialists in hospitals
including neurologists, dermatologists, cardiologists, pedia-
tricians, rheumatologists, internists and ophthalmologists.
Questionnaires were sent and returned by the postalservice. A reminder was sent to non-responding physi-
cians. The questionnaire inquired about consultations
for tick bites and diagnosed erythema migrans in 2010.
For the less common manifestations of disseminated
Lyme borreliosis and persisting symptoms attributed to
Lyme borreliosis, we requested clinical diagnoses for the
two-year period of 2009–2010. The inquired manifesta-
tions of disseminated Lyme borreliosis included borrelial
lymphocytoma, acrodermatitis chronica atrophicans, Lyme
neuroborreliosis, Lyme arthritis, Lyme carditis and ocular
manifestations, and diagnoses of persisting symptoms
attributed to Lyme borreliosis, including Lyme enceph-
alopathy and persisting symptoms after treatment for
Lyme borreliosis.
As every person in the Netherlands is registered with
only one GP, we used the practice populations of reporting
GPs to calculate incidence rates and national estimates of
total numbers among the population of the Netherlands.
As company physicians and medical specialists do not have
a clearly defined patient population at risk, their ques-
tionnaires were only used for proportional comparison
of reported numbers of tick bites and Lyme borreliosis.
Physician responses to the questions on consultations
for tick bites, erythema migrans diagnoses, and size of
practice population were pre-coded in categories to which
values were assigned based on the best fit of an assumed
underlying negative binomial distribution. Incidence rates
for the three categories of Lyme borreliosis were estimated
per 100,000 GP practice population in 2010, and bootstrap
95% confidence intervals (95%CI) for the incidence rates
were calculated by resampling of the GP reports 10,000
times. Bootstrap resampling was required, as the 95%CI for
incidence rates should reflect the number of reporting GPs
and each GP practice population combined, instead of the
size of the practice populations over all reporting GPs. We
screened questionnaires of physicians that reported the top
10% highest incidence of Lyme borreliosis, and excluded
questionnaires with clearly deviating answers or unsat-
isfactory internal consistency (e.g. if a GP reported high
numbers of uncommon disease manifestations such as
Lyme carditis or ocular manifestations, without reporting
common disease manifestations such as erythema migrans,
Lyme neuroborreliosis or Lyme arthritis).
To establish case definitions, we adapted the clinical
case definitions proposed by Stanek et al. [6] with input
from physicians of each medical specialism included in
the survey, recommended to us by their national associa-
tions and input from the Dutch national patients’ associ-
ation for Lyme borreliosis. Additionally, we designed case
definitions for Lyme encephalopathy and persisting sym-
ptoms after treatment for Lyme borreliosis. These were
included to ensure inclusion of all diagnoses used in GP
practice, although these persisting symptoms were ana-
lyzed as one category, because there are no clear criteria
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sponse rate, we inquired about clinical diagnoses of Lyme
borreliosis in the first step of our two-step approach (see
Table 1), not asking the GP to look into laboratory diag-
nostics that had been ordered and judged by medical spe-
cialists in hospitals. Instead, the laboratory diagnostics
were verified in the second part of our two-step approach:
validation of the GP reports, to verify and adjust the crude
incidence rates of disseminated Lyme borreliosis and per-
sisting symptoms attributed to Lyme borreliosis. For this
validation we used additional questionnaires, inquiring de-
tailed information on diagnostic criteria. GPs reporting oneTable 1 Clinical case definitions for Lyme borreliosis,
mainly* adapted from Stanek et al. [1]
Erythema migrans Expanding red or bluish-red patch (= > 5 cm
in diameter), with or without central clearing.
Advancing edge typically distinct, often
intensely coloured, not markedly elevated.
If <5 cm in diameter a history of tick-bite,
a delay in appearance (after the tick bite)
of at least 2 days and an expanding rash
at the site of the tick-bite is required.
Disseminated lyme borreliosis
Borrelial lymphocytoma Painless bluish-red nodule or plaque, usually
on ear lobe, ear helix, nipple or scrotum.




Long-standing red or bluish-red lesions, usually
on the extensor surfaces of extremities. Initial
doughy swelling. Lesions eventually become
atrophic. Possible skin induration and fibroid
nodules over bony prominences.
Lyme neuroborreliosis In adults, mainly meningo-radiculitis, meningitis.
Rarely encephalitis, myelitis, neuritis, cerebral
vasculitis, Bannwarth’s syndrome: painful radiculitis,
lymphocytic meningitis with facial nerve palsies.
In children, mainly meningitis and facial palsy.
Lyme arthritis Recurrent attacks or persisting objective joint
swelling in one or a few large joints.
Alternative explanations must be excluded.
Lyme carditis Acute onset of atrio-ventricular (I–III) conduction
disturbances, rhythm disturbances, sometimes
myocarditis or pancarditis. Alternative
explanations must be excluded.
Ocular manifestations Conjunctivitis, uveitis, papillitis, episcleritis,
keratitis.
Persisting symptoms attributed to lyme borreliosis
Lyme encephalopathy Chronic brain syndrome attributed to Lyme
borreliosis: impaired memory, concentration,
word finding, and sleep; increased fatigue,
sensory irritability, emotional lability, headache
and depression.
Persisting symptoms Persisting symptoms attributed to Lyme
borreliosis after treatment, with or without
active Borrelia infection.
*Additional case definitions for ‘persisting symptoms attributed to Lyme
borreliosis’, which were not proposed by Stanek et al. [1], are indicated with
Italic printing in this table, as well as modifications in the case definition for
‘Lyme neuroborreliosis’.or two cases of Lyme borreliosis received a questionnaire
(see Additional file 1) with regard to applied diagnostic cri-
teria, clinical symptoms, anamnestic tick bites or other
diagnoses of Lyme borreliosis, the year of diagnosis with
Lyme borreliosis, whether the diagnosis was made by
the GP or a medical specialist, treatment, recovery, dif-
ferential diagnoses and how these were ruled out. GPs
reporting more than two cases of Lyme borreliosis received
a short questionnaire (see Additional file 2) on general cri-
teria for diagnosis, inquiring whether a medical specialist is
normally consulted, and whether laboratory outcomes,
clinical symptoms, and anamnestic tick bites or the pres-
ence of other (earlier) Lyme borreliosis manifestations are
taken into account.
Considering the complexities in the diagnosis of Lyme
borreliosis, we categorized the cases of disseminated Lyme
borreliosis according to the likelihood of diagnosis into
‘very likely’, ‘likely’, and ‘possible’ (see Table 2). We labelled
GP reports as ‘invalid reports’, when a GP declared to have
erroneously marked the Lyme borreliosis case on the
questionnaire, or if the diagnosis Lyme borreliosis was
abandoned after further diagnostics. For persisting symp-
toms attributed to Lyme borreliosis we left out the ‘very
likely’ category, as this diagnosis is always uncertain [1]. To
correct for ‘telescoping bias’ [20], we determined the per-
centage of cases diagnosed with disseminated Lyme borre-
liosis within the target period of 2009 and 2010. The target
period for diagnosis for persisting symptoms attributed to
Lyme borreliosis was extended to 2008–2010, to include
the cases who developed Lyme borreliosis in 2008 and
were diagnosed with persisting symptoms attributed to
Lyme borreliosis in 2009–2010. We adjusted the crude in-
cidence rates of our incidence survey according to the pro-
portion of “very likely” diagnosis for disseminated Lyme
borreliosis, and “likely” diagnosis for persisting symptoms
attributed to Lyme borreliosis, and according to the pro-
portion of GP reports within the targeted period of diagno-
sis (2009 and 2010 for disseminated Lyme borreliosis, 2008
to 2010 for persisting symptoms attributed to Lyme). Add-
itionally, we performed a secondary adjustment scenario to
estimate the occurrence of all Lyme borreliosis reports, in-
cluding the less likely reports, because they do contribute
to the disease burden and costs for our society as well as
the individual patient. In this target period adjustment sce-
nario, only invalid reports were excluded and crude inci-
dence was adjusted according to the proportion of GP
reports within the targeted period of diagnosis. Data pre-
processing and statistical analyses were performed in SAS
version 9.1.3, and in R version 3.0.1. In this study, physi-
cians reported only the number of patients diagnosed with
Lyme borreliosis and diagnostic methods used to make
these diagnoses. Therefore, the Medical Ethics Review
Committee UMC Utrecht declared that the Medical
Research Involving Human Subjects Act does not apply to
Table 2 Classification according to likelihood of the
diagnosis, and proportion of diagnoses within the
targeted period, of validated general practitioner (GP)
reported cases of disseminated Lyme borreliosis* and
persisting symptoms attributed to Lyme borreliosis**




Very likely diagnosis (527/590) 89.3% (86.5%-91.6%)
- Diagnosed by a medical specialist.
OR
- Diagnosis based on clinical symptoms,
laboratory diagnosis and anamnesis.
Likely diagnosis (27/590) 4.6% (3.1%-6.7%)
- Diagnosis based on clinical symptoms
and anamnesis.
OR
- Diagnosis based on laboratory
diagnosis and anamnesis.
Possible diagnosis (22/590) 3.7% (2.4%-5.7%)
- Diagnosis not made by medical
specialist.
- Diagnosis not based on clinical
symptoms, laboratory diagnosis and
anamnesis.
- Diagnosis not based on clinical
symptoms and anamnesis.
- Diagnosis not based on laboratory
diagnosis and anamnesis.
OR
- GP reports that the diagnosis is
uncertain.
OR
- Patient proposed diagnosis Lyme
borreliosis, but GP or medical specialist
disagree.
- Diagnosed by an alternative healer.
Invalid report (14/590) 2.4% (1.4%-4.1%)
- GP declared to have erroneously
marked the Lyme borreliosis case on
the questionnaire.
- The diagnosis Lyme borreliosis was
abandoned after further specific
diagnostics.
Diagnosed within targeted period (89/141) 63.1% (54.6%-70.9%)
2009 or 2010





Likely diagnosis (414/544) 76.1% (72.2%-79.6%)
- Diagnosed by a medical specialist.
OR
Table 2 Classification according to likelihood of the
diagnosis, and proportion of diagnoses within the
targeted period, of validated general practitioner (GP)
reported cases of disseminated Lyme borreliosis* and
persisting symptoms attributed to Lyme borreliosis**
(Continued)
- Diagnosis based on clinical symptoms,
laboratory diagnosis and anamnesis.
Possible diagnosis (106/544) 19.5% (16.3%-23.1%)
- Diagnosis based on clinical symptoms
and anamnesis.
OR
- Diagnosis based on laboratory
diagnosis and anamnesis.
OR
- GP reports that the diagnosis is
uncertain.
OR
- GP reports that the diagnosis is
uncertain.
- Patient proposed diagnosis Lyme
borreliosis, but GP or medical specialist
disagree.
- Diagnosed by an alternative healer.
Invalid Report (24/544) 4.4% (2.9%-6.6%)
- GP declared to have erroneously
marked the Lyme borreliosis case on
the questionnaire.
- The diagnosis Lyme borreliosis was
abandoned after further specific
diagnostics.
Diagnosed within targeted period (41/78) 52.6% (41.0%-63.9%)
2008 or 2010
95%CI, 95% confidence interval.
*“Disseminated Lyme borreliosis” includes: borrelial lymphocytoma,
acrodermatitis chronica atrophicans, Lyme neuroborreliosis, Lyme arthritis,
Lyme carditis, ocular manifestations.
**“Persisting symptoms attributed to Lyme borreliosis” includes:
encephalopathy, persisting symptoms after treatment for Lyme borreliosis
with or without active Borrelia infection.
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Results
Among GPs, the response rate to our questionnaire was
39% (3584 out of 9178), representing a total practice
population of 8.7 million persons, which is 53% of the
16.6 million inhabitants of the Netherlands. Among
company physicians, the response rate was 30% (391/
1321) representing one million employees, which is 14%
of our country’s labor force. Among medical specialists,
the response was 35% (1860/5347, hospital catchment
population unknown). Table 3 shows the crude and ad-
justed incidence and national numbers, and 95% CI of
tick bites and Lyme borreliosis in 2010. The incidence
Table 3 Crude and adjusted incidence rates of general practitioner consultations for tick bites and Lyme borreliosis
diagnoses per 100,000 inhabitants, and national estimates of the total numbers among the 16.6 million inhabitants of
the Netherlands in 2010
Incidence (95% CI) per 100,000 National numbers
Crude estimations
Tick bites 494.7 (478.1-511.8) 81,997 (79,253 – 84,827)
Erythema migrans 131.5 (127.1-136.0) 21,802 (21,064 – 22,545)
Disseminated Lyme borreliosis* 13.6 (12.7-14.5) 2,250 (2,103 – 2,400)
Persisting symptoms attributed to Lyme borreliosis** 13.7 (12.7-14.6) 2,263 (2,112 – 2,416)
Adjusted estimations***
Disseminated Lyme borreliosis* 7.7 (7.2-8.2) 1,268 (1,186-1,353)
Persisting symptoms attributed to Lyme borreliosis** 5.5 (5.1-5.8) 905 (845–966)
Target period adjusted estimations****
Disseminated Lyme borreliosis* 8.4 (7.8-8.9) 1,386 (1,296-1,479)
Persisting symptoms attributed to Lyme borreliosis** 6.9 (6.4-7.3) 1,137 (1,061-1,214)
95%CI, 95% confidence interval.
*“Disseminated Lyme borreliosis” includes: borrelial lymphocytoma, acrodermatitis chronica atrophicans, Lyme neuroborreliosis, Lyme arthritis, Lyme carditis,
ocular manifestations.
**“Persisting symptoms attributed to Lyme borreliosis” includes: encephalopathy, persisting symptoms after treatment for Lyme borreliosis with or without active
Borrelia infection.
***Primary adjustment scenario:
The incidence for disseminated Lyme borreliosis was adjusted according to the proportion of very likely diagnosis, and to the proportion of GP reports within the
targeted period of diagnosis 2009 and 2010 (see Table 2).
The incidence for persisting symptoms attributed to Lyme borreliosis was adjusted according to the proportion of likely diagnosis, and to the proportion of GP
reports within the targeted period of diagnosis 2008 to 2010 (see Table 2).
****Target period adjustment scenario:
The incidence for disseminated Lyme borreliosis was adjusted according to the proportion of very likely, likely, and possible diagnosis, and to the proportion of
GP reports within the targeted period of diagnosis 2009 and 2010 (see Table 2).
The incidence for persisting symptoms attributed to Lyme borreliosis was adjusted according to the proportion of likely diagnosis and possible diagnosis, and to
the proportion of GP reports within the targeted period of diagnosis 2008 to 2010 (see Table 2).
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grans diagnoses respectively were 495 (95% CI 478–512)
and 132 (95% CI 127–136) per 100,000 inhabitants in 2010.
All GPs nationwide saw approximately 82,000 patients with
tick bites and 22,000 patients with erythema migrans in
2010. The crude incidence of disseminated Lyme borreliosis
was 13.6 (95% CI 12.7-14.5) per 100,000 inhabitants, and
for persisting symptoms attributed to Lyme borreliosis we
estimated an incidence of 13.7 (95% CI 12.7-14.6) per
100,000 inhabitants. The clinical diagnoses for Lyme borre-
liosis among GPs were mainly (85%) for erythema migrans
(see Figure 1). Of all Lyme-related diagnoses at the GP,
7.5% concerned disseminated Lyme borreliosis, and another
7.5% concerned persisting symptoms attributed to Lyme
borreliosis. Erythema migrans is usually diagnosed by GPs,
but they still represent 33% of all Lyme borreliosis diagno-
ses made by company physicians and 49% of all Lyme bor-
reliosis diagnoses made by medical specialists. For the
latter, diagnoses of disseminated Lyme borreliosis and per-
sisting symptoms attributed to Lyme borreliosis together
represent more than half of their Lyme borreliosis diagno-
ses. Lyme borreliosis diagnoses by company physicians are
predominantly about persisting symptoms, but also include
disseminated Lyme borreliosis (Figure 1).The response rate to our validation questionnaire among
GPs was 47% (855/1832) for the short questionnaire, and
20% (276/1399) for the long questionnaire. As shown in
Table 2, 89.3% of the cases of disseminated Lyme borre-
liosis satisfied our validation criteria for a very likely
diagnosis, 4.6% were categorized as likely, and 3.7% was
categorized as possible. For persisting symptoms attrib-
uted to Lyme borreliosis, 76.1% of the cases satisfied
our criteria for a likely diagnosis and 19.5% was catego-
rized as possible. 2.4% and 4.4% of the reports were cate-
gorized as invalid for disseminated Lyme borreliosis and
persisting symptoms attributed to Lyme borreliosis, re-
spectively. For disseminated Lyme borreliosis, 63.1% of the
cases were diagnosed within the targeted period of 2009
and 2010. For persisting symptoms attributed to Lyme
borreliosis, 52.6% of the cases were diagnosed within the
targeted period of 2008 to 2010.
We estimated the adjusted annual incidence for a very
likely diagnosis of disseminated Lyme borreliosis at 7.7
(95% CI 7.2-8.2) per 100,000 inhabitants in 2009 and 2010.
For persisting symptoms attributed to Lyme borreliosis, we
estimated the adjusted annual incidence at 5.5 (95% CI 5.1-
5.8) per 100,000 inhabitants. Consequently, the national
number of patients annually seen by all GPs in 2009 and
Figure 1 Lyme borreliosis manifestations as a proportion of all Lyme-related diagnoses, by type of physician.
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disseminated Lyme borreliosis and 900 patients with per-
sisting symptoms attributed to Lyme borreliosis (Table 3).
After adjusting, erythema migrans represented 92% of the
clinical diagnoses for Lyme borreliosis reported by the GP,
while 4.7% of the diagnoses concerned disseminated Lyme
borreliosis, and 3.4% concerned persisting symptoms at-
tributed to Lyme borreliosis (see Figure 1). Figure 2 shows
the adjusted incidence per Lyme borreliosis manifestation.
Lyme arthritis and Lyme neuroborreliosis were the most
frequent clinical manifestations of disseminated Lyme bor-
reliosis, with annual incidence rates of 3.0 (95% CI 2.8-3.3)
and 2.6 (95% CI 2.4-2.8) per 100,000 inhabitants. Finally,
the scenario to estimate the occurrence of all Lyme borre-
liosis reports including less likely diagnoses, yielded an an-
nual incidence rate of 8.4 diagnoses per 100,000
inhabitants for disseminated Lyme borreliosis, and 6.9
diagnoses per 100,000 inhabitants for persisting symptoms
attributed to Lyme borreliosis in 2009 and 2010 (see 95%
CI in Table 3).
Discussion
We report the first incidence estimations of disseminated
Lyme borreliosis and persisting symptoms attributed to
Lyme borreliosis, based on a short questionnaire withclinical case definitions, sent to all GPs in the Netherlands.
Furthermore, this is the first reported physician survey on
tick bites and all manifestations of Lyme borreliosis that
covers an entire country. The incidence rates of GP con-
sultations for tick bites and erythema migrans diagnoses
respectively were 495 and 132 per 100,000 inhabitants in
2010. After validation of the GP reports, we estimated an
adjusted annual incidence of 7.7 very likely disseminated
Lyme borreliosis diagnoses per 100,000 inhabitants of the
Netherlands in 2009 and 2010, and 5.5 likely diagnoses of
persisting symptoms attributed to Lyme borreliosis per
100,000 inhabitants in 2009 and 2010 (see Table 3). When
less likely diagnoses were included to estimate the occur-
rence of all Lyme borreliosis reports, the annual incidence
rate was 8.4 for disseminated Lyme borreliosis diagnoses
per 100,000 inhabitants, and 6.9 diagnoses for persisting
symptoms attributed to Lyme borreliosis per 100,000 in-
habitants. These estimates reflect all morbidity attributed
to Lyme borreliosis by GPs. There is an ongoing debate to
what extent past or present Borrelia infection actually
causes this condition of persisting symptoms attributed to
Lyme borreliosis [21]. Nevertheless, about 900 patients
consulted their GP in 2010 for such persisting symptoms
which their GP attributed to Lyme borreliosis. This calls
for further research to the causal mechanisms of this
Figure 2 Adjusted incidence rates of general practitioner
consultations for tick bites and Lyme borreliosis diagnoses per
100,000 inhabitants of the Netherlands in 2010. Vertical bars
represent 95% confidence intervals. *For comparison, the incidence of
tick bite consultations and diagnoses of erythema migrans diagnoses
per 100,000 inhabitants in 2009 was 564 and 134, respectively [18].
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relia infection – to improve clinical care for this substan-
tial patient group.
Not all patients with Lyme borreliosis are correctly diag-
nosed and treated in practice, which may lead to under-
estimation of the disease occurrence. Some publications
on underreporting of Lyme borreliosis state that the true
incidence rate may be two to eight times higher than mea-
sured [22,23]. On the other hand, misdiagnosis and mis-
classification can cause overestimation, which we reduced
through quantification of telescoping bias, and validation
of the likelihood of diagnosis, based on the applied clinical
and laboratory criteria.
We achieved sufficient GP response to account for 53%
of the inhabitants of the Netherlands, which is comparable
to the response rates of the preceding GP surveys. The in-
cidence rates for tick bites and erythema migrans in 2010
were similar to the estimates from the GP survey in 2009,
confirming that the extended survey was consistent with
the earlier GP studies. The small differences can be as-
cribed to the annual fluctuation typically observed in the
surveillance of Lyme borreliosis [5,6].
Comparability of incidence rates between countries is
poor, due to differences in data collection. Accordingly,
divergent incidence rates for Lyme borreliosis have been
reported, and only year-to-year comparisons of theincidence rate within countries can be made [2-4]. How-
ever, countries can be compared as to the proportional
occurrence of clinical manifestations of Lyme borreliosis.
As opposed to physician based studies from other coun-
tries [8-10,12,14], persisting symptoms attributed to
Lyme borreliosis were included in our questionnaire and
case definitions. Excluding persisting symptoms attrib-
uted to Lyme borreliosis, we observed a proportion of
95% of erythema migrans diagnoses relative to all GP-
reported clinical manifestations of Lyme borreliosis. This
is in line with the proportions reported in France and
Southern and Eastern Germany while in Southern
Sweden a lower proportion of 77% was found
[8,10,12,14]. In our study, as well as in France, Germany
and Sweden, the two most commonly GP-reported dis-
seminated manifestations of Lyme borreliosis were Lyme
neuroborreliosis and Lyme arthritis [8-10,12,14]. Borrelial
lymphocytoma, acrodermatitis chronica atrophicans,
Lyme carditis and ocular manifestations were uncommon
in all countries [8-10,12,14].
Comparability between countries is also hampered
by differences in health-care systems. Patients in the
Netherlands are required to consult a GP to be referred to
a medical specialist in a hospital. As a result, erythema
migrans is usually diagnosed and treated by GPs, and not
by medical specialists. This is illustrated by our relatively
low proportion of diagnoses by medical specialists, as com-
pared to GP diagnoses (53% vs 95%), although the propor-
tion of hospital diagnoses of erythema migrans from
Northeastern France (60%) [13], and in a group of hospitals
surveyed in fifteen European countries (59% of Lyme-
related skin manifestations) [11] was only slightly higher.
The latter study of Cimmino et al. in 1994 included the
Netherlands, where six medical specialists reported 42%
skin manifestations, mostly erythema migrans.
Considering all GP-reported Lyme borreliosis, 4.7%
of the diagnoses concerned disseminated Lyme borre-
liosis, and 3.4% concerned persisting symptoms attrib-
uted to Lyme borreliosis (see Figure 1). Due to the high
disease burden and costs associated with disseminated
Lyme borreliosis and persisting symptoms attributed to
Lyme borreliosis, they will contribute greatly to the
public health impact of Lyme borreliosis in our society.
Combined with data on disease burden and costs, the an-
nual numbers per disease manifestation estimated in this
study can be used to assess the annual disease burden and
cost-of-illness of Lyme borreliosis in the Netherlands.
Conclusion
The current study demonstrates that nationwide repre-
sentative incidence rates for GP reported tick bites and
all manifestations of Lyme borreliosis can be obtained
rapidly through a two-step approach of a cross-sectional
retrospective questionnaire among physicians, followed
Hofhuis et al. Parasites & Vectors  (2015) 8:161 Page 8 of 8by a validation questionnaire to adjust for possible mis-
classification and telescoping bias. We report the first
estimations for the occurrence in the Netherlands of dis-
seminated Lyme borreliosis and of persisting symptoms
attributed to Lyme borreliosis, respectively 7.7 and 5.5
GP diagnoses per 100,000 inhabitants. These estimates
are crucial for assessment of the public health impact of
Lyme borreliosis.
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